Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allakos Inc (DE:37Z)
BERLIN:37Z
Allakos (37Z) Stock Price & Analysis
0 Followers
37Z Stock Chart & Stats
Day’s Range€1.15 - €1.15
52-Week Range― - ―
Previous Close€1.12
Volume0.00
Average Volume (3M)N/A
Market Cap
$106.00M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Aug 05, 2024EPS Estimate
-€0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.02Price Target Upside163.40% Upside
Rating ConsensusHold
Number of Analyst Covering6
Allakos News
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsThe initiation of a placebo-controlled Phase 1 trial of AK006 in healthy volunteers is a promising step towards demonstrating safety and biological efficacy.
Drug Development ProgressThe first Phase 1 data for AK006 is expected to connect the mechanistic rationale with clinical efficacy, reinforcing a Market Outperform rating.
Financial StabilityAllakos ended the year with a strong cash position, providing the company with a financial runway into mid-2026, supporting continued development of their therapeutic programs.
Bears Say
Clinical Trial FailureAllakos's randomized, double-blind, placebo-controlled Phase 2 studies testing lirentelimab for atopic dermatitis and chronic spontaneous urticaria failed to meet their primary endpoints.
Drug Development SetbackFollowing recent disappointing Phase 2 results for lirentelimab in atopic dermatitis and chronic spontaneous urticaria, ALLK discontinued further development of lirentelimab and reduced its workforce.
Financial Performance4Q23 Operating Expenses of $65M were above consensus estimates, driven by higher-than-anticipated R&D costs.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
3.83% Other Institutional Investors
96.17% Public Companies and
Individual Investors
37Z FAQ
What was Allakos Inc’s price range in the past 12 months?
Currently, no data Available
What is Allakos Inc’s market cap?
Currently, no data Available
When is Allakos Inc’s upcoming earnings report date?
Allakos Inc’s upcoming earnings report date is Aug 05, 2024 which is in 87 days.
How were Allakos Inc’s earnings last quarter?
Allakos Inc released its earnings results on May 09, 2024. The company reported -€0.754 earnings per share for the quarter, missing the consensus estimate of -€0.411 by -€0.343.
Is Allakos Inc overvalued?
According to Wall Street analysts Allakos Inc’s price is currently Undervalued.
Does Allakos Inc pay dividends?
Allakos Inc does not currently pay dividends.
What is Allakos Inc’s EPS estimate?
Allakos Inc’s EPS estimate is -€0.3.
How many shares outstanding does Allakos Inc have?
Currently, no data Available
What happened to Allakos Inc’s price movement after its last earnings report?
Allakos Inc reported an EPS of -€0.754 in its last earnings report, missing expectations of -€0.411. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Allakos Inc?
Among the largest hedge funds holding Allakos Inc’s share is Blackstone Inc.. It holds Allakos Inc’s shares valued at 11M.
---
Allakos Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€3.02 (163.40% Upside)
€3.02 (163.40% Upside)
Blogger Sentiment
Bearish
DE:37Z Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.06%
12-Months-Change
Fundamentals
Return on Equity
-77.50%
Trailing 12-Months
Asset Growth
-36.96%
Trailing 12-Months
Company Description
Allakos Inc
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
---
37Z Stock 12 Month Forecast
Average Price Target
€3.02
▲(163.40% Upside)
Technical Analysis
Allakos
―
Aldeyra Therapeutics
―
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Best Analysts Covering 37Z
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+50.44%
upgraded a buy rating 5 months ago
Copying Tim Lugo's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +50.44% per trade.
---